2007-11-20 Assigned to SYNTA PHARMACEUTICALS CORP. reassignment SYNTA
PHARMACEUTICALS CORP. ASSIGNMENT OF ASSIGNORS INTEREST (SEE …

2008-03-04 Assigned to SYNTA PHARMACEUTICALS CORP. reassignment SYNTA
PHARMACEUTICALS CORP. ASSIGNMENT OF ASSIGNORS INTEREST (SEE …

US9205086B2 - Cancer therapy using a combination of a Hsp90 inhibitory compounds and a
EGFR inhibitor - Google Patents US9205086B2 - Cancer therapy using a combination of a Hsp90 …

0 [1*] C1= NN= C (C2= NC ([6*])= C ([2*]) C= C2 [3*]) N1 [5*] Chemical compound [1*] C1=
NN= C (C2= NC ([6*])= C ([2*]) C= C2 [3*]) N1 [5*] 0.000 description 83HNYPGUXMIUINJJ …

ZLBLNPKVRABLRF-UHFFFAOYSA-N 6-ethyl-5-hydroxy-2-[4-(1-methylindol-5-yl)-5-
sulfanylidene-1, 2, 4-triazolidin-3-ylidene] pyridin-3-one Chemical compound O= C1C= C …

The present invention relates to substituted triazole compounds and compositions
comprising substituted triazole compounds. The invention further relates to methods of …

2007-09-05 Assigned to SYNTA PHARMACEUTICALS CORP. reassignment SYNTA
PHARMACEUTICALS CORP. ASSIGNMENT OF ASSIGNORS INTEREST (SEE …

6,180,567 6,194,090 6,200,931 6,200,934 6,251,831 6,258,957 6,271,249 6,492.406
6,583,090 6,677.277 6,946,456 7,473,784 2003/0054996 2003/0216369 2003/0216385 …

First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
35966006&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

The present invention relates to substituted triazole com pounds and compositions
comprising Substituted triazole compounds. The invention further relates to methods of …